Institution
Cancer Epidemiology Unit
About: Cancer Epidemiology Unit is a based out in . It is known for research contribution in the topics: Population & Cancer. The organization has 669 authors who have published 1725 publications receiving 93979 citations.
Topics: Population, Cancer, Breast cancer, European Prospective Investigation into Cancer and Nutrition, Prospective cohort study
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This study based on a representative national population sample provides the basis for generalization of the impact of social activity across the entire spectrum, including ethnic and urban-rural variations.
23 citations
••
National Institutes of Health1, International Agency for Research on Cancer2, National and Kapodistrian University of Athens3, Harvard University4, Cancer Epidemiology Unit5, Imperial College London6, Prevention Institute7, University of Granada8, Oklahoma State University Center for Health Sciences9, French Institute of Health and Medical Research10, University of Paris-Sud11, Umeå University12
TL;DR: Evidence supporting the null association between H. pylori infection and pancreatic cancer risk in western European populations is provided, however, the suggested association between chronic corpus atrophic gastritis and pancreati cancer risk warrants independent verification in future studies, and, if confirmed, further studies on the underlying mechanisms.
Abstract: The association between H. pylori infection and pancreatic cancer risk remains controversial. We conducted a nested case-control study with 448 pancreatic cancer cases and their individually matched control subjects, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, to determine whether there was an altered pancreatic cancer risk associated with H. pylori infection and chronic corpus atrophic gastritis. Conditional logistic regression models were applied to calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs), adjusted for matching factors and other potential confounders. Our results showed that pancreatic cancer risk was neither associated with H. pylori seropositivity (OR = 0.96; 95% CI: 0.70, 1.31) nor CagA seropositivity (OR = 1.07; 95% CI: 0.77, 1.48). We also did not find any excess risk among individuals seropositive for H. pylori but seronegative for CagA, compared with the group seronegative for both antibodies (OR = 0.94; 95% CI: 0.63, 1.38). However, we found that chronic corpus atrophic gastritis was non-significantly associated with an increased pancreatic cancer risk (OR = 1.35; 95% CI: 0.77, 2.37), and although based on small numbers, the excess risk was particularly marked among individuals seronegative for both H. pylori and CagA (OR = 5.66; 95% CI: 1.59, 20.19, p value for interaction < 0.01). Our findings provided evidence supporting the null association between H. pylori infection and pancreatic cancer risk in western European populations. However, the suggested association between chronic corpus atrophic gastritis and pancreatic cancer risk warrants independent verification in future studies, and, if confirmed, further studies on the underlying mechanisms.
23 citations
••
TL;DR: In this paper, the clinical impact of subclonal TP53 mutations below 10% to 15% variant allele frequency (VAF) remains unclear, as determined by deep next-generation sequencing.
Abstract: Purpose: In chronic lymphocytic leukemia (CLL), TP53 mutations are associated with reduced survival and resistance to standard chemoimmunotherapy (CIT). Nevertheless, the clinical impact of subclonal TP53 mutations below 10% to 15% variant allele frequency (VAF) remains unclear. Experimental Design: Using a training/validation approach, we retrospectively analyzed the clinical and biological features of TP53 mutations above (high-VAF) or below (low-VAF) the previously reported 10.0% VAF threshold, as determined by deep next-generation sequencing. Clinical impact of low-VAF TP53 mutations was also confirmed in a cohort (n = 251) of CLL treated with fludarabine-cyclophosphamide-rituximab (FCR) or FCR-like regimens from two UK trials. Results: In the training cohort, 97 of 684 patients bore 152 TP53 mutations, while in the validation cohort, 71 of 536 patients had 109 TP53 mutations. In both cohorts, patients with the TP53 mutation experienced significantly shorter overall survival (OS) than TP53 wild-type patients, regardless of the TP53 mutation VAF. By combining TP53 mutation and 17p13.1 deletion (del17p) data in the total cohort (n = 1,220), 113 cases were TP53 mutated only (73/113 with low-VAF mutations), 55 del17p/TP53 mutated (3/55 with low-VAF mutations), 20 del17p only, and 1,032 (84.6%) TP53 wild-type. A model including low-VAF cases outperformed the canonical model, which considered only high-VAF cases (c-indices 0.643 vs. 0.603, P Conclusions: TP53 mutations affected OS regardless of VAF. This finding can be used to update the definition of TP53 mutated CLL for clinical purposes.
23 citations
••
German Cancer Research Center1, International Agency for Research on Cancer2, Institut Gustave Roussy3, Université Paris-Saclay4, University of Paris-Sud5, National and Kapodistrian University of Athens6, University of Milan7, University of Naples Federico II8, Prevention Institute9, University of Granada10, Cancer Epidemiology Unit11, Imperial College London12, University of Ioannina13, University College Dublin14
TL;DR: A positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset is observed and further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification.
Abstract: The gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within a prospective cohort. Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 11 SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the 11 SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27). In this prospective nested case-control study, we observed a positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification.
23 citations
••
Utrecht University1, Imperial College London2, Copenhagen University Hospital3, French Institute of Health and Medical Research4, German Cancer Research Center5, Prevention Institute6, University of Tromsø7, University of Oslo8, Andalusian School of Public Health9, Lund University10, Umeå University11, University of Cambridge12, Cancer Epidemiology Unit13, International Agency for Research on Cancer14, Aarhus University15
TL;DR: The present study suggests that fish consumption has no appreciable association with body-weight gain.
Abstract: Fish consumption is the major dietary source of EPA and DHA, which according to rodent experiments may reduce body fat mass and prevent obesity. Only a few human studies have investigated the association between fish consumption and body-weight gain. We investigated the association between fish consumption and subsequent change in body weight. Women and men (n 344 757) participating in the European Prospective Investigation into Cancer and Nutrition were followed for a median of 5.0 years. Linear and logistic regression were used to investigate the associations between fish consumption and subsequent change in body weight. Among women, the annual weight change was 5.70 (95% CI 4.35, 7.06), 2.23 (95% CI 0.16, 4.31) and 11.12 (95% CI 8.17, 14.08) g/10 g higher total, lean and fatty fish consumption per d, respectively. The OR of becoming overweight in 5 years among women who were normal weight at enrolment was 1.02 (95% CI 1.01, 1.02), 1.01 (95% CI 1.00, 1.02) and 1.02 (95% CI 1.01, 1.04) g/10 g higher total, lean and fatty consumption per d, respectively. Among men, fish consumption was not statistically significantly associated with weight change. Adjustment for potential over-or underestimation of fish consumption did not systematically change the observed associations, but the 95% CI became wider. The results in subgroups from analyses stratified by age or BMI at enrolment were not systematically different. In conclusion, the present study suggests that fish consumption has no appreciable association with body-weight gain.
22 citations
Authors
Showing all 669 results
Name | H-index | Papers | Citations |
---|---|---|---|
Richard Peto | 183 | 683 | 231434 |
Kay-Tee Khaw | 174 | 1389 | 138782 |
Silvia Franceschi | 155 | 1340 | 112504 |
Timothy J. Key | 146 | 808 | 90810 |
Hans-Olov Adami | 145 | 908 | 83473 |
Alicja Wolk | 135 | 778 | 66239 |
Paolo Vineis | 134 | 1088 | 86608 |
Lars Klareskog | 131 | 697 | 63281 |
Eva Negri | 129 | 1010 | 66735 |
John A. Baron | 128 | 609 | 61182 |
Jack Cuzick | 128 | 754 | 79979 |
Anders Ekbom | 116 | 613 | 51430 |
C. La Vecchia | 115 | 817 | 53460 |
Valerie Beral | 114 | 471 | 53729 |
Carlo La Vecchia | 112 | 1265 | 56282 |